2002
DOI: 10.1007/s005950200153
|View full text |Cite
|
Sign up to set email alerts
|

A Pediatric Amino Acid Solution for Total Parenteral Nutrition Does Not Affect Liver Function Test Results in Neonates

Abstract: These findings indicate that this amino acid solution for pediatrics has no significant effect on LFTs in neonates, even when high doses of amino acids (3.5 g/kg per day) are infused.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1

Citation Types

0
5
0

Year Published

2003
2003
2021
2021

Publication Types

Select...
6
2
1

Relationship

0
9

Authors

Journals

citations
Cited by 11 publications
(5 citation statements)
references
References 13 publications
0
5
0
Order By: Relevance
“…While there is a general consensus on the dosing of parenteral amino acids, there are only two small RCTs comparing different amino acid dose strategies (i.e. high versus low amino acids) in term and late preterm infants (23,24) . Whilst both studies found that amino acid doses did not affect liver function, they did not report on important clinical outcomes such as mortality, growth and neurodevelopment.…”
Section: Discussionmentioning
confidence: 99%
“…While there is a general consensus on the dosing of parenteral amino acids, there are only two small RCTs comparing different amino acid dose strategies (i.e. high versus low amino acids) in term and late preterm infants (23,24) . Whilst both studies found that amino acid doses did not affect liver function, they did not report on important clinical outcomes such as mortality, growth and neurodevelopment.…”
Section: Discussionmentioning
confidence: 99%
“…Therefore, conventional amino acid solutions used in adults might not be suitable for the neonates who require additional essential amino acids, in which taurine supplementation in the pediatric amino acid solution might be logically useful to prevent PNALD [2]. However, a study using TrophAmine, a taurine-containing amino acid solution, did not show significant improvement in the incidence of PNALD [7]. In animal studies, cysteine and homocysteine supplementation in the PN, as a precursor for gluthathione producing osmotic driving force in bile acid-independent bile flow, could also improve hepatic steatosis and increase bile flow in rats [8,9].…”
Section: Pathogenesis and Risk Factors For Pnaldmentioning
confidence: 91%
“…There is paucity of data on the efficacy and safety of PN in this age group. Two small studies enrolled late preterm and term neonates, but neither reported on major clinical outcomes [33,34]. PN is widely used in Australian facilities in late preterm and term neonates who are not enterally fed.…”
Section: Pn In Late Preterm (34 +0 To 36 + 6 Weeks) and Term Neonatesmentioning
confidence: 99%